Related Articles
Efficacy of timing‑dependent infusion of nivolumab in patients with advanced gastric cancer
The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy
Progression‑free survival of first‑line treatment with molecular‑targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma
Simple predictors for the completion of scheduled gemcitabine‑cisplatin regimens based on real‑world urothelial cancer data
First-line single-agent chemotherapy for patients with recurrent or metastatic gastric cancer with poor performance status